ACT Capital Partners, L.P.’s Mineralys Therapeutics MLYS Stock Holding History

ACT Capital Partners, L.P.’s Portfolio MLYS Stock Details MLYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.2M	Buy	+87,400	New	+$2.38M	1.43%	21

Other funds holding MLYS

Catalys Pacific Tokyo, Japan $210M AUM 33.18% 1-Year Est. Return

Laurion Capital Management New York $6.21B AUM 32.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Andera Partners Paris $176M AUM 1.8% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

ACT Capital Partners, L.P.'s MLYS Position: Q3 2026 in Review

ACT Capital Partners, L.P. opened a new position in Mineralys Therapeutics (MLYS) in Q3 2026: 87,400 shares worth $2.2M. The stake represents 1.43% of the portfolio and ranks #21 among its holdings.

68 funds tracked by Wall St. Rank hold MLYS as of Q3 2026.

ACT Capital Partners, L.P. held 87,400 shares of Mineralys Therapeutics worth $2.2M as of Q3 2026.
Mineralys Therapeutics was a new ACT Capital Partners, L.P. position in Q3 2026.
Mineralys Therapeutics made up 1.43% of ACT Capital Partners, L.P.'s portfolio in Q3 2026, its #21 holding.
68 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q3 2026.

Based on ACT Capital Partners, L.P.'s 13F filing for Q3 2026, filed 6 Nov 2026.